Analyst Activity – Jefferies Group Initiates Coverage On Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR) With a Buy

0

Analyst Ratings For Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR)

Today, Jefferies Group initiated coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR) with a Buy with a price target of $10.00.

Some recent analyst ratings include

  • 3/27/2018-Jefferies Group initiated coverage with a Buy rating.
  • 2/19/2018-Chardan Capital Reiterated Rating of Buy.
  • 11/27/2017-Piper Jaffray Upgrade from a “Neutral ” rating to a ” Overweight” rating.
  • 9/18/2017-William Blair Upgrade from a “Market Perform ” rating to a ” Outperform” rating.

Recent Insider Trading Activity For Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR) has insider ownership of 4.60% and institutional ownership of 26.88%.

  • On 3/15/2018 Christopher Richard Anzalone, CEO, sold 300,000 with an average share price of $7.43 per share and the total transaction amounting to $2,229,000.00.
  • On 3/13/2018 Christopher Richard Anzalone, CEO, sold 100,000 with an average share price of $7.43 per share and the total transaction amounting to $743,000.00.
  • On 3/5/2018 Bruce D Given, COO, sold 20,000 with an average share price of $6.73 per share and the total transaction amounting to $134,600.00.
  • On 1/1/2018 Bruce D Given, COO, sold 20,000 with an average share price of $3.69 per share and the total transaction amounting to $73,800.00.
  • On 10/14/2016 Douglas B. Given, Director, sold 12,000 with an average share price of $6.72 per share and the total transaction amounting to $80,640.00.
  • On 8/23/2016 Kenneth Allen Myszkowski, CFO, sold 6,900 with an average share price of $8.00 per share and the total transaction amounting to $55,200.00.
  • On 8/22/2016 Kenneth Allen Myszkowski, CFO, sold 13,100 with an average share price of $8.00 per share and the total transaction amounting to $104,800.00.

Recent Trading Activity for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) closed the previous trading session at 7.71 up +0.77 11.10% with 458980 shares trading hands.